casimersen
FDA approved for the treatment of Duchenne muscular dystrophy.
Also Known As:
SRP-4045; amondys 45
Networked: 9
relevant articles (0 outcomes,
2 trials/studies)
Bio-Agent Context: Research Results
Experts
| 1. | Arechavala-Gomeza, Virginia:
1 article
(01/2022)
|
| 2. | Bahal, Raman:
1 article
(01/2022)
|
| 3. | Kasina, Vishal:
1 article
(01/2022)
|
| 4. | Laddha, Ankit P:
1 article
(01/2022)
|
| 5. | López-Martínez, Andrea:
1 article
(01/2022)
|
| 6. | Manautou, José E:
1 article
(01/2022)
|
| 7. | Pradeep, Sai Pallavi:
1 article
(01/2022)
|
| 8. | Soblechero-Martín, Patricia:
1 article
(01/2022)
|
| 9. | Tu, Mei-Juan:
1 article
(01/2022)
|
| 10. | Yu, Ai-Ming:
1 article
(01/2022)
|
Related Diseases
| 1. | Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker)
|
| 2. | COVID-19
01/01/2022
- " With the development of viable RNA technologies, such as chemistry and pharmaceutics, eight antisense oligonucleotides (ASOs) (fomivirsen, mipomersen, eteplirsen, nusinersen, inotersen, golodirsen, viltolarsen and casimersen), one aptamer (pegaptanib), and three small interfering RNAs (siRNAs) (patisiran, givosiran and lumasiran) have been approved by the United States Food and Drug Administration (FDA) for therapies, and two mRNA vaccines (BNT162b2 and mRNA-1273) under Emergency Use Authorization for the prevention of COVID-19. "
|
|
Related Drugs and Biologics
Related Therapies and Procedures